Literature DB >> 7574454

Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients.

P Remy1, Y Samson, P Hantraye, A Fontaine, G Defer, J F Mangin, G Fénelon, C Gény, F Ricolfi, V Frouin.   

Abstract

To assess the efficacy of fetal mesencephalic grafts in Parkinson's disease, it is important to know if the grafted cells survive and are functional. Positron emission tomography (PET) and [18F]fluorodopa ([18F]dopa) have been used to demonstrate the survival of the grafted cells, but the relationship of [18F]dopa uptake changes in the grafted striatum to motor function remains unclear. We investigated this question with 16 serial PET scans in 5 severe parkinsonian patients unilaterally grafted in whom we found a significant and progressive increase of the [18F]dopa uptake in the grafted putamen. The number of patients was too small to assess the sensitivity of [18F]dopa PET scans in individual patients. Yet, by analyzing the 16 serial PET scans we found a correlation between the [18F]dopa uptake (Ki) in the grafted putamen and the percentage of daily time spent "on," suggesting that Ki changes have a functional meaning. In addition, the Ki values were correlated with the contralateral finger dexterity to the same extent in both the grafted and nongrafted putamen. These results indicate that [18F]dopa uptake reflects the motor function of the opposite side of the body, similarly in the grafted and ungrafted putamen, at least in terms of these tasks. Finally, extrapolating from these correlations offers the suggestion that clinical optimal results of the graft could be achieved if the graft brings the Ki values in the putamen to about two standard deviations of mean control values.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7574454     DOI: 10.1002/ana.410380406

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  22 in total

1.  Novel therapies in the search for a cure for Huntington's disease.

Authors:  M F Beal; P Hantraye
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

Review 2.  The design of clinical trials for cell transplantation into the central nervous system.

Authors:  Pierre Cesaro
Journal:  NeuroRx       Date:  2004-10

3.  Molecular imaging of cell transplantation in Parkinson's disease.

Authors:  Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04       Impact factor: 9.236

Review 4.  Positron emission tomography imaging of transplant function.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-10

Review 5.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

Review 6.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

Review 7.  Update on Molecular Imaging in Parkinson's Disease.

Authors:  Zhen-Yang Liu; Feng-Tao Liu; Chuan-Tao Zuo; James B Koprich; Jian Wang
Journal:  Neurosci Bull       Date:  2017-12-27       Impact factor: 5.203

8.  Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes.

Authors:  Yilong Ma; Chengke Tang; Thomas Chaly; Paul Greene; Robert Breeze; Stanley Fahn; Curt Freed; Vijay Dhawan; David Eidelberg
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

Review 9.  Cell Therapy for Parkinson's Disease: New Hope from Reprogramming Technologies.

Authors:  Zhiguo Chen
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

Review 10.  PET-based molecular imaging in neuroscience.

Authors:  A H Jacobs; H Li; A Winkeler; R Hilker; C Knoess; A Rüger; N Galldiks; B Schaller; J Sobesky; L Kracht; P Monfared; M Klein; S Vollmar; B Bauer; R Wagner; R Graf; K Wienhard; K Herholz; W D Heiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.